PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 77 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,151,903 | -46.8% | 129,011 | -11.9% | 0.01% | -43.5% |
| Q2 2023 | $4,045,971 | -20.4% | 146,487 | -33.7% | 0.02% | -25.8% |
| Q1 2023 | $5,082,793 | +64.0% | 220,991 | -22.2% | 0.03% | +47.6% |
| Q4 2022 | $3,099,695 | +44.6% | 284,115 | +11.7% | 0.02% | +23.5% |
| Q3 2022 | $2,144,000 | +77.8% | 254,340 | +272.5% | 0.02% | +30.8% |
| Q2 2020 | $1,206,000 | +136.0% | 68,279 | -5.6% | 0.01% | +85.7% |
| Q1 2020 | $511,000 | -21.0% | 72,357 | -21.2% | 0.01% | +16.7% |
| Q4 2019 | $647,000 | +289.8% | 91,831 | +565.0% | 0.01% | +200.0% |
| Q3 2019 | $166,000 | -39.2% | 13,810 | -36.4% | 0.00% | -50.0% |
| Q1 2019 | $273,000 | +42.9% | 21,700 | -23.6% | 0.00% | +33.3% |
| Q4 2018 | $191,000 | -30.0% | 28,400 | +7.2% | 0.00% | -25.0% |
| Q3 2018 | $273,000 | – | 26,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |